These data demonstrate that the alteration of the Spry4 gene identified in Kallmann syndrome-diseased people produces a protein variant that is capable of inhibiting RTK-mediated processes in normal human embryonic fibroblasts, a cell type in which the original variant is unable to achieve a detectable effect. The gene discussed is SPRY4; the disease is Kallmann syndrome.